News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
73,375 Results
Type
Article (1947)
Company Profile (2)
Press Release (71426)
Section
Business (25341)
Career Advice (9)
Deals (4553)
Drug Development (8186)
FDA (1807)
Job Trends (802)
News (37036)
Policy (3569)
Tag
2027 BioCapital Standard (1)
Academia (97)
Accelerated approval (5)
ADA (2)
Allergies (21)
Alliances (8171)
ALS (15)
Alzheimer's disease (184)
Antibody-drug conjugate (ADC) (112)
Approvals (1968)
Artificial intelligence (35)
ASCO (37)
Autoimmune disease (34)
Automation (2)
Bankruptcy (8)
Best Places to Work (586)
BIO (9)
Biosimilars (92)
Biotechnology (5)
Bladder cancer (32)
Brain cancer (8)
Breast cancer (63)
Cancer (648)
Cardiovascular disease (26)
Career advice (9)
CAR-T (15)
CDC (1)
Cell therapy (59)
Cervical cancer (5)
Clinical research (7705)
Collaboration (332)
Compensation (27)
Complete response letters (7)
COVID-19 (209)
CRISPR (1)
C-suite (96)
Cystic fibrosis (8)
Data (844)
Depression (16)
Dermatology (11)
Diabetes (43)
Diagnostics (643)
Digital health (7)
Drug discovery (42)
Drug pricing (1)
Duchenne muscular dystrophy (43)
Earnings (8161)
Events (7597)
Executive appointments (75)
FDA (2315)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (153)
Gene editing (7)
Generative AI (1)
Gene therapy (41)
GLP-1 (84)
Government (242)
Grass and pollen (1)
Guidances (39)
Healthcare (1096)
Hematology (14)
HIV (6)
Huntington's disease (3)
IgA nephropathy (23)
Immunology and inflammation (7)
Immuno-oncology (11)
Indications (28)
Infectious disease (235)
Inflammatory bowel disease (25)
Inflation Reduction Act (1)
Influenza (14)
Intellectual property (41)
IPO (1640)
Job creations (242)
Job search strategy (9)
JPM (3)
Kidney cancer (1)
Layoffs (6)
Legal (953)
Liver cancer (19)
Longevity (3)
Lung cancer (118)
Lymphoma (55)
Machine learning (1)
Manufacturing (130)
Marketing (3)
MASH (19)
Medical device (1176)
Medtech (1194)
Mergers & acquisitions (3111)
Metabolic disorders (112)
mRNA (7)
Multiple sclerosis (24)
NASH (1)
Neurodegenerative disease (35)
Neuropsychiatric disorders (7)
Neuroscience (338)
NextGen: Class of 2026 (219)
Non-profit (64)
Obesity (38)
Opinion (1)
Ovarian cancer (35)
Pain (20)
Pancreatic cancer (30)
Parkinson's disease (49)
Partnered (4)
Patents (76)
Patient recruitment (77)
Peanut (1)
People (5188)
Pharmaceutical (2)
Pharmacy benefit managers (5)
Phase 1 (2096)
Phase 2 (3273)
Phase 3 (2916)
Pipeline (1204)
Policy (1)
Postmarket research (242)
Preclinical (713)
Press Release (2)
Prostate cancer (26)
Radiopharmaceuticals (25)
Rare diseases (84)
Real estate (606)
Regulatory (3052)
Reports (6)
Research institute (100)
Rett syndrome (1)
RNA editing (3)
RSV (3)
Schizophrenia (21)
Series A (32)
Series B (24)
Service/supplier (1)
Sickle cell disease (8)
Spinal muscular atrophy (5)
Sponsored (1)
Startups (425)
Stomach cancer (2)
Supply chain (13)
Vaccines (47)
Venture capital (7)
Weight loss (17)
Women's health (7)
Date
Last 7 days (53)
Last 30 days (186)
Last 365 days (2797)
2026 (1590)
2025 (2685)
2024 (3254)
2023 (3817)
2022 (7010)
2021 (6380)
2020 (5879)
2019 (3858)
2018 (3012)
2017 (3560)
2016 (3172)
2015 (4031)
2014 (3021)
2013 (2600)
2012 (2776)
2011 (2902)
2010 (2663)
Location
Africa (88)
Alabama (4)
Arizona (13)
Arkansas (1)
Asia (22279)
Australia (2498)
California (800)
Canada (467)
China (506)
Colorado (5)
Connecticut (23)
Delaware (6)
Europe (13442)
Florida (87)
Georgia (17)
Illinois (43)
India (51)
Indiana (27)
Japan (337)
Kansas (5)
Louisiana (2)
Maine (4)
Maryland (124)
Massachusetts (636)
Michigan (9)
Minnesota (37)
Missouri (3)
Nebraska (3)
Nevada (10)
New Hampshire (1)
New Jersey (486)
New York (283)
North Carolina (121)
Northern California (339)
Ohio (6)
Oregon (1)
Pennsylvania (149)
Puerto Rico (1)
Rhode Island (1)
South America (109)
South Carolina (1)
Southern California (393)
Tennessee (2)
Texas (61)
United States (3060)
Utah (29)
Vermont (1)
Virginia (60)
Washington D.C. (3)
Washington State (61)
Wisconsin (7)
73,375 Results for "recce ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd. today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “ Copolymer and Method for Treatment of Bacterial Infection , ” for its anti-infectives, with expiry in 2035.
May 8, 2024
·
3 min read
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
Recce Pharmaceuticals Ltd. today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.
May 13, 2024
·
4 min read
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
Recce Pharmaceuticals Ltd today announced it has been issued a trademark registration for RECCE ® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.
March 22, 2024
·
3 min read
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
Recce Pharmaceuticals Ltd today announced its primary anti-infective candidate, RECCE ® 327 (R327), has been added to the World Health Organization’s (WHO) list of Antibacterial Agents in Clinical Development and Preclinical Development.
June 20, 2024
·
3 min read
Drug Development
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
Recce Pharmaceuticals Ltd today announced it received Human Research Ethics Committee (HREC) approval to commence a Phase II trial assessing its lead candidate, RECCE® 327 (R327), as a topical, broad-spectrum gel for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
June 25, 2024
·
4 min read
Drug Development
Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327
Recce Pharmaceuticals Ltd today announced positive data from a Phase I/II trial for urinary tract infections (UTIs) and urosepsis, demonstrating that its lead candidate, RECCE® 327 (R327), administered intravenously is safe and efficacious against Escherichia coli (E. coli).
July 1, 2024
·
5 min read
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
April 4, 2024
·
4 min read
Press Releases
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
February 27, 2025
·
3 min read
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
Recce Pharmaceuticals Ltd today announced the successful batch completion under Good Manufacturing Practices (GMP) for its lead candidate, RECCE® 327 (R327), with the patented manufacturing process now producing 5,000 GMP doses of R327 per week.
April 17, 2024
·
4 min read
Drug Development
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
Recce Pharmaceuticals Ltd today announced it completed dosing healthy subjects in the latest cohort of its Phase I/II trial, evaluating its lead candidate, RECCE ® 327 (R327).
March 19, 2024
·
3 min read
1 of 7,338
Next
